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Abstract: Gestational diabetes mellitus (GDM) annually affects 35,000 pregnancies in the United
Kingdom, causing suboptimal health outcomes to the mother and child. Obesity and excessive
gestational weight gain are risk factors for GDM. The Institute of Medicine recommends weight targets
for women that are overweight and obese, however, there are no clear guidelines for women with
GDM. Observational data suggest that modest weight loss (0.6–2 kg) after 28 weeks may reduce risk of
caesarean section, large-for-gestational-age (LGA), and maternal postnatal glycaemia. This protocol
for a multicentre randomised double-blind controlled trial aims to identify if a fully controlled
reduced energy diet in GDM pregnancy improves infant birthweight and reduces maternal weight
gain (primary outcomes). A total of 500 women with GDM (National Institute of Health and Care
Excellence (NICE) 2015 criteria) and body mass index (BMI) ≥25 kg/m2 will be randomised to receive
a standard (2000 kcal/day) or reduced energy (1200 kcal/day) diet box containing all meals and snacks
from 28 weeks to delivery. Women and caregivers will be blinded to the allocations. Food diaries,
continuous glucose monitoring, and anthropometry will measure dietary compliance, glucose levels,
and weight changes. Women will receive standard antenatal GDM management (insulin/metformin)
according to NICE guidelines. The secondary endpoints include caesarean section rates, LGA, and
maternal postnatal glucose concentrations.
Keywords: gestational diabetes; pregnancy; study protocol; randomised controlled trial;
large-for-gestational age; diet; dietary intervention; maternal or gestational weight gain; continuous
glucose monitoring (CGM); neonatal outcomes; neonatal hypoglycaemia; neonatal growth;
maternal obesity
1. Introduction
Gestational diabetes (GDM) affects around 5% of pregnant women in the United Kingdom (UK) [1]
and increases the risk of suboptimal materno-fetal outcomes and is associated with pre-pregnancy
obesity and excessive gestational weight gain [2–5]. GDM is usually diagnosed at 24–28 weeks’
gestation and identifies women at risk of type 2 diabetes in later life. Although excessive gestational
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weight gain in early pregnancy (0–28 weeks) is well-established as a risk factor for GDM [3], the role of
weight control in women after the diagnosis of GDM, from 28 weeks to delivery, is unclear.
Weight gain is a normal part of a healthy pregnancy, but excessive weight gain can contribute to
poor outcomes for both the mother and child. Excessive gestational weight gain is currently defined
using the Institute of Medicine guidelines (2009) based upon a woman’s pre-pregnancy body mass
index (BMI) [6]. Normal weight, overweight, and obese women are advised to gain 11.4–15.9 kg,
6.8–11.4 kg, and 5.0–9.1 kg, respectively [6]. Many pregnant women exceed these targets and gain
excessive weight [7]. It is also unclear if these targets are suitable for women with GDM, who are
already at higher risk of adverse pregnancy outcomes compared with women without diabetes [5] and
who may benefit from lower gestational weight gain targets [8]. It is unclear if maternal weight gain
after GDM diagnosis remains important to prevent adverse maternal and baby outcomes, but there are
data that suggest this is the case. A study by Harper and colleagues showed that for every 1 lb per
week increase in weight in women after diagnosis with GDM, there was a 36–83% increased risk for
pre-eclampsia, caesarean section, macrosomia, and large-for-gestational-age (LGA) (7). The guidelines
of the National Institute of Health and Care Excellence (NICE) for diabetes in pregnancy highlight
the importance of pre-pregnancy and post-partum weight control in women with GDM, but do not
provide guidance on gestational weight gain targets [9]. There is currently limited evidence to guide
clinical practice in this area.
Excessive weight gain has been associated with multiple adverse outcomes. In the general obstetric
population, excessive gestational weight gain has been associated with hypertensive disorders in
pregnancy [10], LGA [11], macrosomia [12], depression [13], and may also be linked to infant death [14].
In later life, women with excessive gestational weight gain during pregnancy are at increased risk
of type 2 diabetes and cardiometabolic disease [15], which may be linked to the weight gained in
pregnancy not being completely lost after the birth [16]. Offspring of women with excessive gestational
weight gain have increased body weight, increased fat mass, and increased blood pressure in childhood,
raising concerns about obesity and diabetes risk in later life [17–19].
Women with GDM and who are overweight or obese pre-pregnancy may benefit from minimal
gestational weight gain in later pregnancy to improve both short and longer term health outcomes.
Theoretically, reduced late gestational weight gain may improve infant birth weight and impact upon
postpartum weight retention and future cardiometabolic risk. However, few studies have ever assessed
pregnancy outcomes following moderate energy restriction in women with GDM [20,21]. These studies
have been useful in providing evidence for maternal and neonatal outcomes, however they did not
provide comprehensive evidence that having a strict food allocation over a set period of time could
impact on these outcomes, as addressed in this protocol.
The clinical trial protocol presented here is a double blind, fully controlled dietary intervention
using a novel approach of diet boxes. Diet boxes have become very popular commercially and contain
all of an individual’s meals and snacks for the week delivered to their home or workplace. Meals are
designed to be nutritionally balanced, healthy, appetising and require only minimal time and effort
to cook at home. As participants can be randomised to receive a box providing reduced or standard
energy diet, this overcomes many of the challenges faced in controlling and blinding nutritional studies
in free-living pregnant volunteers.
The aim of this trial is to identify if a reduced energy diet in 500 pregnant women diagnosed
with GDM can reduce gestational weight gain, improve pregnancy outcomes, and reduce postnatal
glucose concentrations.
2. Trial Population and Methods
2.1. Trial Design and Ethical Approvals
DiGest (Dietary intervention in Gestational diabetes) is a multicentre fully controlled randomised
double-blind dietary controlled trial. It involves recruiting 500 participants who have been diagnosed
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with GDM to take part in an eating energy controlled diet during the last 8–10 weeks of their pregnancy.
The trial is estimated to take three years and is based in the East Anglia region. It is being conducted in
accordance with the Declaration of Helsinki, and the protocol was approved by the Research Ethics
Committee in Cambridge, UK (reference 18/WM/0191) and the National Health Service (NHS) Health
Research Authority (IRAS 242924; ISRCTN 37866).
2.2. Participant Eligibility
Eligible pregnant women are identified following diagnosis of GDM at 20 to 30 + 6 weeks’
gestation using a standard clinical 75 g oral glucose tolerance test (OGTT) in accordance with the
NICE glucose thresholds (fasting ≥5.6 mmol/L and ≥7.8 mmol/L at two hours) [9]. Eligible women
require a pre-pregnancy BMI ≥25 kg/m2 (based on measured weight at booking, using validated scales),
singleton pregnancy confirmed by ultrasound, and planned antenatal care at the same or another
participating trial centre throughout pregnancy. Women will be recruited by research midwives, nurses,
or by their physician/obstetrician. Study documentation will be provided in advance and women who
wish to participate will be offered an appointment to discuss the study and consent to participate.
All women will give their written informed consent before participation in any trial related activities.
2.3. The Following Exclusion Criteria Will Be Applied
Women with evidence of multiple pregnancy or severe congenital abnormality on ultrasound;
termination planned; pre-existing comorbidities such as renal failure, severe liver disease, cardiac
failure, and psychiatric conditions requiring in-patient admission; medications at the time of the
OGTT that may interfere with results (e.g., high dose steroids, immunosuppressants); complications
such as preterm labour, severe anaemia, or intrauterine growth restriction (IUGR) at GDM diagnosis;
haemoglobin A1c (HbA1c) at diagnosis of GDM of >48 mmol/mol; previous diabetes diagnosis;
specialised dietary requirement (e.g., vegan or severe nut allergy); and weight loss >5% based between
pre-pregnancy weight (weight first measured in pregnancy at booking) and 28 weeks’ gestation.
2.4. Design of The Intervention
The diet boxes were developed in association with our industrial partner Mayfield Foods Ltd.,
Oxfordshire, UK. The diet boxes contain 2000 kcal/day (control) or reduced energy (1200 kcal/day)
comprising 40% carbohydrate, 25% protein, and 35% fat. The macronutrient levels are similar between
both diets, however, portion sizes in the control arm are significantly larger to account for the increase
in calories.
Macronutrient composition was designed to be in line with current clinical practice for gestational
diabetes to ensure the standard calorie diet box was comparable to a standard GDM diet. There is little
clear evidence for dietary modification in GDM, but many centres recommend a slight reduction in
carbohydrate [22] and slight increase in protein for satiety. Upon discussion with our trial steering
committee, we agreed 40% carbohydrate and 25% protein, as higher protein consumption has been
associated with reduced birthweight [23].
Carbohydrate sources were from low glycaemic index foods in line with the NICE guidelines [24].
The diet box meals do contain naturally occurring sugars, for example, in fruit, but they do not contain
any added sugar, preservatives, or artificial flavour enhancers, and adhere to NHS food safety advice
for pregnant women [25,26].
Participants order their food weekly from the DiGest study website. Each participant will receive
seven breakfasts, lunches, and dinners, all supplied as frozen pre-prepared meals; seven snack-packs;
and an additional optional pack containing raw vegetables and salads. As breakfast can often challenge
blood glucose levels in women with GDM, both intervention and control groups have the same
breakfast options (300 kcal), with the remaining daily dietary energy intake split between lunch, dinner,
and snacks. To maximise choice, lunch and dinner options are interchangeable. Snacks are delivered
in a daily snack-pack, which contains a similar mixture of carbohydrate, protein, and fat containing
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foods. Altogether, participants are provided with 10 breakfast options, 22 lunch/dinner options, and 8
snack-packs (Table 1). New menu items are added continuously and in response to feedback. There
are sufficient options to cater for vegetarian and pescatarian women. Women are allowed to drink
sugar-free, calorie-free drinks such as water, tea, or coffee with a teaspoon of milk, or sugar-free fizzy
drinks. These are not provided in the diet box.
Lunch and dinner options contain 1–3 portions of vegetables per meal, and there are additional
portions in the snack-pack and vegetable/salad packs. Initial reviews of the frozen meals, which were
piloted on health care professionals (n = 16) and participants (n = 5), suggested that participants missed
crunchy vegetables, and the vegetable pack was added to address this. Participants can choose between
4–9 portions of fruit and vegetables every day. Calcium requirements (1200 mg/day recommended by
World Health Organisation (WHO) [27] are met using leafy green vegetables such as rocket, spinach,
kale, wholemeal flour, milk, yogurt, cheese and cream. We did not supply extra calcium as this is not
widely recommended in the United Kingdom and carries some risks [28,29]. However, many pregnant
women also take multivitamins that contain a daily dose of 200–500 mg of calcium.
Feedback on the diet boxes will be received verbally from participants after the first diet box has
been delivered. Women are also asked to complete a single questionnaire about the diet provided
during the intervention. This feedback allows us to adjust the meal choices on offer, improve the diet
box composition while still maintaining the macronutrient balance, and address any issues to ensure
the diet boxes meet participants’ expectations.
Table 1. Example food options for a week on the study. Each day will come with an additional
snack-pack and there is also a salad/veg box provided if requested.
Weekday Breakfast Lunch Dinner Snack Pack
Monday Porridge with nutsand jam Chilli bean wrap Turkey roast
Boiled egg, satsuma, small
cheese
Tuesday Cheese and hamomelette with rosti
Mushroom
stroganoff with rice
Macaroni cheese
with kale
Apple, Belgian Chocolate
covered rice cake, spiced seeds
Wednesday Breakfast roll
Chicken schnitzel,
wedges, and green
beans
Venison sausage in
red wine sauce
with sprouts
Cottage cheese, Ryvita,
satsuma
Thursday Spiced omelettewith Sag Aloo Seafood lasagne
Beef madras with
rice
Peperami (mini), orange,
Belgian chocolate rice cake
Friday Blueberry yogurt Edamame and fetawrap
Salmon with lemon
Puy lentils
Peperami (mini), pear, spiced
seeds, popcorn
Saturday Granola Spiced Moroccanchicken wrap
Fish goujon,
wedges, and
minted peas
Small cheese, apple,
Philadelphia snack light herbs,
and breadsticks
Sunday
Cheese and
mushroom
omelette
Thai red chicken
curry with rice
Vegetarian bean
stew, rice, and
halloumi
Satsuma, Belgian chocolate
covered rice cake, spiced seeds
Weekly Veg/Salad
Pack
Contains a range of vegetables and salad options including carrots, broccoli, cauliflower, baby
tomatoes, cucumber, lettuce, celery, and red pepper
2.5. Baseline Measurements and Randomisation
An outline of the protocol is detailed in Figure 1. Women who wish to participate and have given
written informed consent are randomised before 30 + 6 weeks’ gestation.
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Figure 1. DiGest (Dietary intervention in Gestational diabetes) protocol summary. Abbreviations: 
OGTT, oral glucose tolerance test; GDM, gestational diabetes mellitus; ANC, antenatal clinic; CGM, 
continuous glucose monitoring; TFEQ–18, three factor eating questionnaire 18; EQ5DL, EuroQol 5 
dimension quality of life questionnaire; HbA1c, hemoglobin A1c; INTAKE24, dietary recall 
questionnaire over 24 hour period; DXA, dual-energy X-ray absorptiometry scan; ADP–PEA, air 
displacement plethysmography pea pod. 
2.5.1. Clinical Measures 
At recruitment, baseline blood pressure and anthropometric measurements (including weight, 
height, waist, mid upper arm circumference (MUAC) and neck circumferences, and skinfold 
thickness (SFT)) will be assessed. Participants will be measured barefoot and in light clothing. Weight 
will be recorded to the nearest 100 g using a calibrated electronic scale (Seca Hammer Steindamm). 
Figure 1. DiGest (Dietary intervention in Gestational diabetes) protocol summary. Abbreviations: OGTT,
oral glucose tolerance test; GDM, gestational diabetes mellitus; ANC, antenatal clinic; CGM, continuous
glucose monitoring; TFEQ–18, three factor eating questionnaire 18; EQ5DL, EuroQol 5 dimension
quality of life questionnaire; HbA1c, hemoglobin A1c; INTAKE24, dietary recall questionnaire over 24 h
period; DXA, dual-energy X-ray absorptiometry scan; ADP–PEA, air displacement plethysmography
pea pod.
2.5.1. Clinical Measures
At recruitment, baseline blood pressure and anthropometric measurements (including weight,
height, waist, mid upper arm circumference (MUAC) and neck circumferences, and skinfold thickness
(SFT)) will be assessed. Participants will be measured barefoot and in light clothing. Weight will be
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recorded to the nearest 100 g using a calibrated electronic scale (Seca Hammer Steindamm). Height
will be assessed to the nearest 0.1 cm with a calibrated wall-mounted stadiometer (SECA 286; Seca,
Birmingham, UK). Body mass index (BMI; in kg/m2) will be calculated as weight divided by square
height. The circumferences will be measured to the nearest 0.1 cm with a nonstretchable fiber-glass
tape (Chasmors Ltd., London, UK). Waist circumference will be defined as the midpoint between
the lowest rib margin and the iliac crest; MUAC as the mid-point between the tip of the shoulder
and the tip of the elbow (olecranon process and the acromium); and the neck circumference as the
midway of the neck, between the midcervical spine and midanterior neck. The SFT will be performed
on the left side of the body from multiple sites, including triceps, biceps, suprailiac, and subscapular
using a calibrated Harpenden skinfold caliper (Baty International, UK). Blood pressure will be taken
once seated using a calibrated automatic oscillometric sphygmomanometer (Dinamap, machine) and
systolic and diastolic blood pressure will be recorded. Measurements will be performed by trained
research staff, following standard protocols. Quality control workshops will be set up during the trial,
where study team members will conduct measurements alongside expert examiners to reinforce the
importance of standardised procedures and to assess inter- and intra-observer errors.
2.5.2. Laboratory Measures
Fasting blood will be taken by a nurse, research midwife, or trained phlebotomist at baseline,
36 weeks, and 6 weeks post-partum, processed within two hours, for laboratory analysis of markers of
glucose metabolism (glucose, insulin, c-peptide, HbA1c), lipid profiles, and full blood count (if not
already taken for clinical purposes). HbA1c is collected in an Ethylenediaminetetraacetic (EDTA) tube
(Starstedt, Leicester, UK) and measured in local laboratories using a Tosoh High performance liquid
chromatography (HPLC) analyser and aligned to the International Federation of Clinical Chemistry
(IFCC) method. All laboratories participate in quality assurance and have acceptable performance.
Serum and plasma form blood will be stored at −80 ◦C for future novel biomarkers of interest. Batch
analysis of biomarkers will be performed by a centralized laboratory based at the Cambridge Biomedical
Campus. A whole blood sample is collected in an EDTA tube (Starstedt, Leicester, UK) and stored at
4 ◦C for later DNA extraction. A lithium heparin tube (Starstedt, Leicester, UK) is used for insulin and
C-peptide determination and is stored on ice immediately after withdrawal prior to centrifugation.
2.6. Dietary Assessment and Compliance
2.6.1. Assessment of Normal Dietary/Energy Intake
Participants will be asked to complete questionnaires including the EuroQol Quality of life
(EQ-5D-5L), three factor eating questionnaire 18 (TFEQ-18) [30], and online multiple pass 24 h dietary
recalls (using the “Intake24” programme) [31]. Validity of total energy intake reported by Intake24 was
compared to total energy expenditure using doubly labelled water in 98 U.K. adults [31]; the correlations
were 0.31 (one recall), 0.47 (two repeated recalls), and 0.39 (three repeated recalls), respectively.
2.6.2. Assessment of Adherence to the Diet Boxes
Women are asked to complete an Intake24 and a three-day food diary while wearing a masked
continuous glucose monitor (CGM) for 7–10 days (Dexcom G6, San Diego USA), which is used for
assessment of typical diet. Women are also asked to complete three-day food diaries at various points,
while on the diet boxes, to assess adherence while wearing a CGM. Participants are asked to give
specific details on all their food consumption including portion sizes and drinks. They are asked to
ensure that one weekend day is included in this three-day monitoring period.
2.6.3. Randomisation and Blinding
At the first visit, a unique participant number will be allocated by the recruitment team. Using the
participant number, women will be randomly assigned to the energy restriction arm (1200 kcal/day) or
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the standard dietary arm (2000 kcal/day). This randomisation protocol was designed by a statistician
based upon participant numbers and has been integrated within the online food ordering system.
The allocation, therefore, is blinded from the participant, research team, and clinical teams, but is
automatically available to the industrial partner for preparation of the diet box. This process is audited
on a monthly basis to ensure the randomization is running smoothly for both arms of the study.
2.6.4. Monitoring Period
Participants are advised to weigh themselves twice weekly on standard Bluetooth scales, provided
on loan from the study team, to ensure that any weight loss is gradual and stable. They will have
regular contact with the research team, which will be documented. Women will attend their standard
antenatal appointments in which they will have weight checks, urinalysis, and ultrasound growth
scans. Standard GDM care will be offered by clinical teams according to the NICE guidelines [9].
In brief, women are given diet and lifestyle advice after diagnosis and receive a glucometer with
instructions on self-monitoring blood glucose. Medication (metformin and / or insulin) will be offered
to women with glucose levels persistently over NICE targets (5.3 mmol/L fasting and 7.8 mmol/L at
one hour) in line with the NICE guidance. Doses are up-titrated to achieve improved glycaemic control.
Clinical teams making treatment decisions are unaware of the participant’s allocation [9].
2.7. Intervention Visits
Women are invited for a visit at 32 (visit 2) and 36 weeks (visit 3) gestation, using ±7 days for
each visit. During visits 2 and 3, participants will be weighed, have blood pressure taken, a CGM
sensor inserted, and asked to complete a three-day food diary while wearing the concurrent CGM
during the next 7–10 days. At visit 2, women will be offered participant information leaflets about
voluntary procedures around the time of the birth, specifically placental biopsy, cord blood collection,
and infant anthropometry measures to be taken at birth and six weeks postnatal. These procedures
will be discussed again at visit 3, when specific consent for these additional voluntary procedures
will be sought. Visit 3 will include completing all the questionnaires, maternal blood measures, and
maternal anthropometry performed in visit 1.
Visit 4 will take place six weeks postpartum. To avoid inconvenience to participants, this visit
replaces the standard postnatal glucose test offered to all women after GDM [9]. At this visit, participants
will have their anthropometry measurements repeated as per baseline and body composition measured
by dual-energy X-ray absorptiometry (DXA) scan (Hologic, Manchester, UK) at sites where this facility is
available. A urine sample will be taken for microalbuminuria. Participants will be asked to complete the
EuroQol EQ5D and TFEQ-18 and provide brief details about infant feeding choices. A final CGM sensor
will be applied and worn for 7–10 days. Neonatal anthropometry and air displacement plethsmography
(ADP)-PEA pod (Cosmed Ltd., Bicester, UK) body composition measurements (where available) will
be undertaken at this visit (subject to specific additional written consent). Anthropometry will be
performed by trained paediatric research nurses or research assistants, following standard procedures.
These measurements will include weight, length, MUAC, waist and head circumferences, and skinfold
thickness (SFT). Weight will be measured to the nearest 1 g using a Seca 757 electronic baby scale
(Seca, Birmingham, UK). Length will be assessed to the nearest 0.1 cm using an Infantometer (Seca 416,
Birmingham, UK). Skinfold thickness will be performed in triplicate at four sites (triceps, subscapular,
flank, quadriceps) on the left side of the body using a calibrated Holtain Tanner/Whitehouse Skinfold
Caliper (Holtain, Crymych, UK). From ADP-PEA pod, body composition information including body
volume, body density, body surface area, total fat mass (FM), total fat-free mass (FFM), and percentage
body fat (%BF) will be derived.
2.8. Study Outcomes
There are two co-primary endpoints; maternal weight change between enrolment and 36 weeks’
gestation and neonatal birthweight. Neonatal sex-appropriate SD scores (SDS) will be calculated for
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weight and length measurements (with adjustments for gestational age at birth) using customised
centiles (UK 1990 growth reference using LMS growth software LMSgrowth) [32].
Secondary Outcomes are Categorised for the Neonate and the Mother as Follows
Neonatal: Gestational age at delivery, preterm delivery (<37 weeks), large/small-for-gestational
age (using local, national, and international centiles and customised centiles), amniotic fluid glucose,
cord blood C-peptide, admission to the neonatal intensive care unit (NICU), duration of admission to
NICU, neonatal jaundice requiring phototherapy, Apgar scores, body composition and anthropometry,
neonatal hypoglycaemia (defined as a capillary glucose <2.6 mmol/L on one or more occasions, within
the first 48 h of life starting at least 30 min after birth, and necessitating treatment either with 40% glucose
gel administered to the buccal mucosa and/or with intravenous dextrose), neonatal nasogastric feeding,
and feeding type on discharge from hospital. Infant feeding choices and feeding history will also be
examined at six weeks postpartum. Neonatal anthropometry; for each of the four skinfold thickness
measurements, an internal standard deviation score (SDS) will be calculated, using residuals from a
linear regression model, adjusting for infancy age, gestational age at birth, and sex. Mean skinfold
thickness SDS will be used in analyses. Birth ponderal index will be calculated by dividing the infant’s
birthweight by its birth length cubed (kg/m3). Secondary analysis for sex-appropriate SDS scores will
also be assessed using different growth centiles such as GROW centiles [33] and INTERGROWTH
centiles [34].
Maternal outcomes at 32 weeks, 36 weeks and postpartum: Maternal outcomes to be
studied include maternal weight, BMI, glycaemia (CGM metrics as per the international consensus
recommendations [35], HbA1c), cardiometabolic health (blood pressure, lipids, fasting insulin, fasting
glucose), maternal food choice and eating behaviour, quality of life, treatments administered for
GDM, birth modality and complications, and postpartum glycaemia (measured by two-point OGTT
and CGM).
2.9. Sample Size Justification
Retrospective data assessing the effect of late gestational weight gain (GWG) upon pregnancy
outcomes were used to inform the sample size calculation [36]. The following sample size examples
are based upon alpha 0.05 and power 0.9.
In the retrospective study, women had a standard deviation of 2 kg for late GWG and <3 kg for
total GWG. Allowing for a standard deviation of 3 kg and a 1 kg difference between groups, 190 women
per group will be required to give 90% power for the primary maternal endpoint.
The neonatal primary endpoint will be standardised birthweight. Recruitment of 175 women per
group will give 90% power for identification of a 0.3 sd difference in standardised birthweight. As the
standard deviation for birthweight was 508 g, this broadly equates to a difference in birthweight of
150 g.
A study size of 500 participants will provide sufficient statistical power and will allow for a
20–25% withdrawal rate. This sample size will also give sufficient power to detect secondary outcomes:
• To identify an increase in LGA (odds ratio (OR) 2.25 at 80% power).
• To identify a difference in maternal glycaemia at 36 weeks, for example, differences in mean CGM
glucose (0.3 mmol/L difference), time in target (8% difference in time in target (3.5–7.8 mmol/L;
>100 min per day), which has been associated with clinically relevant differences in neonatal
outcomes) [8].
• To identify a 0.7 mmol/L difference in maternal postnatal two-hour OGTT glucose.
Several secondary analyses will be performed. A per protocol analysis will be performed in
participants with >80% compliance and at least four weeks’ exposure to the intervention. Data will be
used in a qualitative way to assess predictors for withdrawal or poor compliance. Consent will also be
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taken to collect and analyse outcomes for women who withdraw from the study, to allow assessment
of reasons for withdrawal and their bearing upon outcomes.
2.10. Statistical Analysis
An intention to treat analysis of the co-primary outcomes will be based on t-tests between trial
arms and linear regression models with adjustment for baseline variables and the stratification variable
of study centre using a fixed effects model. In addition, the model for maternal gestational weight
change will be adjusted for baseline weight as an explanatory variable. The potential role of other
explanatory variables such as pre-pregnancy BMI or information from the questionnaires will be
investigated in sensitivity analyses. Secondary outcomes will be examined through regression analyses
(linear or logistic) appropriate for the type of outcome being considered. A further secondary analysis
will be performed to assess if main results are altered with addition of early GWG to the regression
model. Safety analyses will be performed to assess any quantitative difference in effects, rates of
small-for-gestational-age (SGA)/IUGR, stillbirth, neonatal hypoglycaemia, and admission to NICU.
3. Discussion
This protocol describes a novel free-living fully controlled dietary energy restriction trial in
pregnant women with GDM to assess the effect on maternal weight gain and neonatal birthweight.
Using diet boxes to provide all meals and snacks to participants in both arms of the trial facilitates
blinding and randomisation, in order to control dietary energy intake insofar as possible. It also
ensures that dietary intake is in line with guidelines for a safe and healthy diet during pregnancy.
The objective of this study is to assess the impact of maternal dietary energy restriction on maternal
and neonate outcomes. Previous attempts to define clear targets for gestational weight gain in women
with GDM have been hindered by two main concerns: firstly, that calorie restriction in pregnancy may
be harmful, and secondly, that intervening after 28 weeks is too late. Data from the Dutch Famine
Winter cohort have demonstrated that women exposed to severe calorie restriction during pregnancy
(<500–800 kcal/day) have infants of lower birth weight who are at higher risk of SGA and IUGR [37].
However, in clinical and research populations with more modest energy restriction, there has been
no evidence of harmful effects. For example, women with hyperemesis gravidarum give birth to
infants with no evidence of growth restriction [38]. Studies of modest energy restriction in GDM have
demonstrated no adverse effects [20,21], with SGA rates comparable to the baseline population [20,21].
A recent study demonstrated that a reduced energy diet in pregnant women with GDM is acceptable to
patients and associated with a good quality of life [39]. Hodson and colleagues assessed the effects of a
low calorie diet in 16 women with GDM on liver triacylglycerol content [39]. Women were recruited at
21–34 weeks’ gestation and followed a four-week diet supplying 1200 kcal/day (50% carbohydrate,
25% protein, 25% fat). The diet was well tolerated and women lost a mean of 0.4 ± 0.4 kg per week
during the four-week intervention. The study was not randomised and did not aim primarily to
assess pregnancy outcomes [39]. This study also demonstrated that calorie restriction in pregnancy
is achievable in women with GDM and was well tolerated. The study used a research dietician to
give one-to-one support to each participant using a meal plan. Although this was very successful,
this delivery mode for the intervention placed a high burden on participants and required substantial
staff resources.
Interventions to change the overall energy intake of the diet in free-living conditions are challenging,
with many studies having design limitations that reduce the validity of the results (reviewed in [40]).
For example, randomisation and blinding in free-living trials is challenging and often not performed.
Nutritional studies may be entirely self-reported and portion sizes cannot be controlled [41,42]. The diet
boxes may support participants in following the prescribed diet by providing all the meals and snacks
in an easy to follow format. The portions are controlled and all the nutrition required for a safe and
healthy diet during pregnancy is provided.
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Controlling gestational weight gain after 28 weeks may only give a relatively short time for
intervening, but previous work has suggested that this still could have beneficial effects upon pregnancy
outcomes [21]. Although there are no long term data about dietary interventions after 28 weeks, overall,
gestational weight gain has an impact upon women’s weight for up to 15 years after the pregnancy [16].
There are several studies that support the potential benefits of controlling gestational weight gain after
a diagnosis of GDM, and that address the issues of safety and timescales. We recently completed a
retrospective study of 547 women with GDM [36]. Overall total gestational weight gain (0–36 weeks)
was associated with increased rates of LGA, caesarean section, and reduced rates of vaginal deliveries.
Late GWG was also associated with postpartum glucose homeostasis with a positive association with
two-hour OGTT glucose concentration on the postpartum OGTT, raising the possibility that controlling
GWG for a short 8–10 week period could lead to longer-term beneficial effects upon glucose tolerance
and diabetes incidence [36].
DiGest is a randomised controlled blinded trial assessing whether an energy restricted diet in
pregnant women with GDM can improve pregnancy outcomes for mother and child. Although the
current evidence base suggests that controlling pregnancy-related weight gain can improve health
outcomes, much of the traditional advice given to women in pregnancy today with growing rates of
overweight and obesity is inappropriate. The common myth of ‘eating for two’ may be particularly
detrimental for women with GDM.
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